• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Lack of Efficacy of SGLT2-i in Severe Pneumonia Related to Novel Coronavirus (nCoV) Infection: No Little Help from Our Friends.钠-葡萄糖协同转运蛋白2抑制剂（SGLT2-i）在新型冠状病毒（nCoV）感染所致重症肺炎中疗效欠佳：朋友们帮不上大忙。
Diabetes Ther. 2020 Jul;11(7):1605-1606. doi: 10.1007/s13300-020-00844-8. Epub 2020 May 23.
2
[Pregnancy with new coronavirus infection: clinical characteristics and placental pathological analysis of three cases].[新型冠状病毒感染合并妊娠：三例临床特征及胎盘病理分析]
Zhonghua Bing Li Xue Za Zhi. 2020 May 8;49(5):418-423. doi: 10.3760/cma.j.cn112151-20200225-00138.
3
2019 novel coronavirus (2019-nCoV) outbreak: A new challenge.2019 新型冠状病毒（2019-nCoV）爆发：新的挑战。
J Glob Antimicrob Resist. 2020 Jun;21:22-27. doi: 10.1016/j.jgar.2020.02.021. Epub 2020 Mar 7.
4
Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV.新型冠状病毒 2019-nCoV：流行情况、与 SARS-CoV 和 MERS-CoV 的生物学和临床特征比较。
Eur Rev Med Pharmacol Sci. 2020 Feb;24(4):2012-2019. doi: 10.26355/eurrev_202002_20379.
5
Detection and analysis of nucleic acid in various biological samples of COVID-19 patients.检测和分析 COVID-19 患者各种生物样本中的核酸。
Travel Med Infect Dis. 2020 Sep-Oct;37:101673. doi: 10.1016/j.tmaid.2020.101673. Epub 2020 Apr 18.
6
[A pathological report of three COVID-19 cases by minimal invasive autopsies].[三例新冠病毒病病例微创尸检病理报告]
Zhonghua Bing Li Xue Za Zhi. 2020 May 8;49(5):411-417. doi: 10.3760/cma.j.cn112151-20200312-00193.
7
[Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia].[29例2019新型冠状病毒肺炎患者临床特征分析]
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):203-208. doi: 10.3760/cma.j.issn.1001-0939.2020.03.013.
8
Potential Maternal and Infant Outcomes from (Wuhan) Coronavirus 2019-nCoV Infecting Pregnant Women: Lessons from SARS, MERS, and Other Human Coronavirus Infections.新型冠状病毒（2019-nCoV）感染孕妇的母婴潜在结局：来自 SARS、MERS 和其他人类冠状病毒感染的教训。
Viruses. 2020 Feb 10;12(2):194. doi: 10.3390/v12020194.
9
Detection of 2019-Novel Coronavirus (2019-nCoV) by rRT-PCR at Mymensingh Medical College, Mymensingh, Bangladesh.孟加拉国迈门辛医学院利用逆转录实时荧光定量聚合酶链反应（rRT-PCR）检测2019新型冠状病毒（2019-nCoV）
Mymensingh Med J. 2020 Jul;29(3):589-595.
10
2019 Novel Coronavirus (COVID-19) Pneumonia: Serial Computed Tomography Findings.2019 新型冠状病毒（COVID-19）肺炎：连续计算机断层扫描结果。
Korean J Radiol. 2020 Apr;21(4):501-504. doi: 10.3348/kjr.2020.0112. Epub 2020 Feb 26.

引用本文的文献

1
The Effect of Sodium-Glucose Cotransporter-2 Inhibitors on COVID-19 Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study Using the Common Data Model.钠-葡萄糖协同转运蛋白2抑制剂对2型糖尿病COVID-19患者的影响：一项使用通用数据模型的回顾性队列研究
J Clin Med. 2024 Jan 12;13(2):431. doi: 10.3390/jcm13020431.
2
Effect of Antidiabetic Therapy on Clinical Outcomes of COVID-19 Patients With Type 2 Diabetes: A Systematic Review and Meta-Analysis.抗糖尿病治疗对 2 型糖尿病合并 COVID-19 患者临床结局的影响：系统评价和荟萃分析。
Ann Pharmacother. 2023 Jul;57(7):776-786. doi: 10.1177/10600280221133577. Epub 2022 Oct 29.
3
Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Pneumonia and Septic Shock.钠-葡萄糖共转运蛋白 2 抑制剂与肺炎和感染性休克风险。
J Clin Endocrinol Metab. 2022 Nov 25;107(12):3442-3451. doi: 10.1210/clinem/dgac558.
4
Impact of overlapping risks of type 2 diabetes and obesity on coronavirus disease severity in the United States.2 型糖尿病和肥胖症重叠风险对美国冠状病毒疾病严重程度的影响。
Sci Rep. 2021 Sep 9;11(1):17968. doi: 10.1038/s41598-021-96720-x.
5
Therapy of Type 2 Diabetes in Patients with SARS-CoV-2 Infection.新型冠状病毒感染合并 2 型糖尿病患者的治疗。
Int J Mol Sci. 2021 Jul 16;22(14):7605. doi: 10.3390/ijms22147605.
6
Perspectives of Antidiabetic Drugs in Diabetes With Coronavirus Infections.抗糖尿病药物在糖尿病合并冠状病毒感染中的应用前景
Front Pharmacol. 2021 Jan 29;11:592439. doi: 10.3389/fphar.2020.592439. eCollection 2020.
7
Inpatient Hyperglycemia Management and COVID-19.住院患者高血糖管理与2019冠状病毒病
Diabetes Ther. 2021 Jan;12(1):121-132. doi: 10.1007/s13300-020-00966-z. Epub 2020 Dec 5.
8
Sodium-Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions.钠-葡萄糖协同转运蛋白2抑制剂与主要COVID-19结局：有前景的机制、相互矛盾的数据及引人关注的临床决策
Diabetes Ther. 2020 Dec;11(12):3003-3005. doi: 10.1007/s13300-020-00942-7. Epub 2020 Oct 14.
9
SGLT-2 inhibitors as cardioprotective agents in COVID-19.钠-葡萄糖协同转运蛋白2抑制剂作为COVID-19中的心脏保护剂
Heart Lung. 2020 Nov-Dec;49(6):875-876. doi: 10.1016/j.hrtlng.2020.09.002. Epub 2020 Sep 22.
10
Sodium-glucose co-transporter-2 inhibitors and susceptibility to COVID-19: A population-based retrospective cohort study.钠-葡萄糖协同转运蛋白 2 抑制剂与 COVID-19 易感性：一项基于人群的回顾性队列研究。
Diabetes Obes Metab. 2021 Jan;23(1):263-269. doi: 10.1111/dom.14203. Epub 2020 Oct 19.

本文引用的文献

1
Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease.钠-葡萄糖协同转运蛋白 2 抑制剂对全身和组织低度炎症的影响：对糖尿病并发症和心血管疾病的潜在贡献。
Diabetes Metab. 2018 Dec;44(6):457-464. doi: 10.1016/j.diabet.2018.09.005. Epub 2018 Sep 26.
2
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review.SGLT2 抑制剂与心血管获益的机制：最新综述。
Diabetologia. 2018 Oct;61(10):2108-2117. doi: 10.1007/s00125-018-4670-7. Epub 2018 Aug 22.
3
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.恩格列净如何降低心血管死亡率？来自 EMPA-REG OUTCOME 试验中介分析的见解。
Diabetes Care. 2018 Feb;41(2):356-363. doi: 10.2337/dc17-1096. Epub 2017 Dec 4.
4
Empagliflozin decreases myocardial cytoplasmic Na through inhibition of the cardiac Na/H exchanger in rats and rabbits.恩格列净通过抑制大鼠和兔子心脏中的钠/氢交换体来降低心肌细胞质中的钠含量。
Diabetologia. 2017 Mar;60(3):568-573. doi: 10.1007/s00125-016-4134-x. Epub 2016 Oct 17.
5
Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis.能量代谢重编程能否解释 EMPA-REG OUTCOME 研究中有益的心脏肾脏结局？一个统一的假说。
Diabetes Care. 2016 Jul;39(7):1115-22. doi: 10.2337/dc16-0542.

Lack of Efficacy of SGLT2-i in Severe Pneumonia Related to Novel Coronavirus (nCoV) Infection: No Little Help from Our Friends.

作者信息

Bossi Antonio Carlo, Forloni Franco, Colombelli Paolo Luigi

机构信息

Endocrine Unit-Diabetes Regional Center, ASST Bergamo Ovest, Treviglio, BG, Italy.

Internal Medicine Division, ASST Bergamo Ovest, Treviglio, BG, Italy.

出版信息

Diabetes Ther. 2020 Jul;11(7):1605-1606. doi: 10.1007/s13300-020-00844-8. Epub 2020 May 23.

DOI:10.1007/s13300-020-00844-8
PMID:32447736
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7244936/
Abstract
摘要